

Applicants : WEI, et al.
U.S. Serial No.: 10/650,365
Filed : August 28, 2003
Page : 2

RECEIVED
CENTRAL FAX CENTER

DEC 14 2005

In the August 23, 2005 Office Action, Examiner further did not consider the following references listed on Form PTO/SB/08A attached hereto as **Exhibit A** and further listed below:

- CN-1099799A, March 3, 1995, Hauptmann, et al.
- CN-1120848A, April 17, 1996, Reichert, et al.
- CN-1186120A, July 1, 1998, Huang, Yun Qiang
- CN-1217660A, May 26, 1999, Blatt, Larry and Klein, Michael
- CN-1256148A, June 14, 2000, Zhang, et al.
- CN-1291198A, April 11, 2001, Hogarth, et al.
- CN-1384116A, December 11, 2002, Jiang, Chun Lei and Wang, Yun Xia
- CN-1098103C, January 8, 2003, Blatt, Lawrence M. and Taylor, Milton W.
- CN-1062565C, February 28, 2001, Zhao, et al.

Examiner further did not consider the following references listed on Form PTO/SB/08B attached hereto as **Exhibit B** and further listed below:

- CAO Hongpeng, TAO Peizhen. Effect of Anti-HBV of 6 Drugs Include Lamivudine. Natl Med J China, 2001,81(16):1004-1007

RECEIVED
CENTRAL FAX CENTER

DEC 14 2005

Applicants : WEI, et al.
U.S. Serial No.: 10/650,365
Filed : August 28, 2003
Page : 3

- FEI Junhua, QIN Laiyin, FAN Guiling, et al. Clinical Observation of Effect on Treatment of Chronic Hepatitis B by a Combination of Interferon α and Lamivudine. Shandong Medical Journal, 1999,39(11): 3-4
- GAO Yuanfu, LIU Guanglin, XIA Zhengkun, et al. Treatment of hepatitis virus related pediatric nephritis with IFN- α . Academic Journal of Jinlin Hospital, 1999,12(1):24-26
- LEI Binjun, LU Yuhong, QIU Yanqiu, et al. Observation on Clinical Treatment of Chronic Hepatitis B by Purified Human Leucocyte Interferon- α . Chinese Journal of Practical Internal Medicine, 1995,15(3):155-157
- LANG Zhenwei, HAN Honglei, XU Dejun, et al. Observation on Serology and Histology of Patients with Chronic Hepatitis B after Interferon Treatment. Chin J Infect Dis., 2002,20(2):97-100
- WANG Xiangye, LI Xuegang. Comparing Effect of Three Drugs on Turning HBeAg to Negative. Qianwei Medical Journal, 1994,11(4):197-198

Applicants have reviewed the file and submit that the Examiner should consider these references when considering the patentability of the claimed invention. A copy of the said references listed herewith and on form PTO/08/B in Exhibit A were included in the Supplemental Information Disclosure Statement filed on June 14, 2005. Further, a copy of the said references listed herewith and on Form PTO/08/A in Exhibit B were included in the November 13, 2003 Information Disclosure Statement. It is unclear in the record why the references are not being considered by the Examiner.

Applicants : WEI, et al.
U.S. Serial No.: 10/650,365
Filed : August 28, 2003
Page : 4

Accordingly, since the references were submitted for the record, Applicants respectfully request the Examiner to consider them.

If a telephone interview would be of assistance in advancing the prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891. Conversely, authorization is also hereby given to credit the amount of any overpayment to Deposit Account No. 50-1891.

I hereby certify that this paper is being facsimile transmitted to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Fax No.: (571) 273-8300

on the date shown below.

Albert Wai-Kit Chan 12/14/05
Albert Wai-Kit Chan Date
Reg. No. 36,479

Respectfully submitted,

Albert Wai-Kit Chan
Albert Wai-Kit Chan
Registration No. 36,479
Attorney for Applicants
Law Offices of
Albert Wai-Kit Chan, LLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, New York 11357
Tel: (718) 799-1000
Fax: (718) 357-8615
Email: chunk@kitchanlaw.com